• Citer

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

par Cortes, Javier;Vahdat, L.;Blum, J.;Twelves, Chris J;Campone, M.;Roche, Henri;Bachelot, Thomas;Awada, Ahmad ;Paridaens, R. ;Goncalves, A.;Shuster, D.;Wanders, Jantien;Fang, F.;Gurnani, R.;Richmond, E.;Cole, Patricia E;Ashworth, Simon;Allison, M.
Référence Journal of clinical oncology, 28, 25, page (3922-3928)
Publication Publié, 2010-09

Article révisé par les pairs

• Détails
• Contenu

Titre:	Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
Auteur:	Cortes, Javier; Vahdat, L.; Blum, J.; Twelves, Chris J; Campone, M.; Roche, Henri; Bachelot, Thomas; Awada, Ahmad; Paridaens, R.; Goncalves, A.; Shuster, D.; Wanders, Jantien; Fang, F.; Gurnani, R.; Richmond, E.; Cole, Patricia E; Ashworth, Simon; Allison, M.
Informations sur la publication:	Journal of clinical oncology, 28, 25, page (3922-3928)
Statut de publication:	Publié, 2010-09
Sujet CREF:	Cancérologie
MeSH keywords:	Adult
	Aged
	Aged, 80 and over
	Antineoplastic Agents -- adverse effects -- therapeutic use
	Breast Neoplasms -- drug therapy -- pathology
	Disease-Free Survival
	Drug Administration Schedule
	Ethers, Cyclic
	Female
	Furans -- adverse effects -- therapeutic use
	Humans
	Ketones -- adverse effects -- therapeutic use
	Middle Aged
	Peripheral Nervous System Diseases -- chemically induced
	Retreatment
Note générale:	Clinical Trial, Phase II
	Journal Article
	Multicenter Study
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:0732-183X
	info:doi/10.1200/JCO.2009.25.8467
	info:pii/JCO.2009.25.8467
	info:pmid/20679609